Glucosamine sulphate: an umbrella review of health outcomes
07 марта 2021 года
05:45
Glucosamine sulphate: an umbrella review of health outcomes
Текст новости:
Title: Glucosamine sulphate: an umbrella review of health outcomes
Author, co-author: Veronese, N.; Demurtas, J.; Smith, L.; Reginster, Jean-Yves; Bruyère, Olivier; Beaudart, Charlotte; Honvo, Germain; Maggi, S
Abstract: Background and Aims: Glucosamine sulphate (GS) can be used as background therapy in people affected by knee osteoarthritis (OA). Knowledge regarding the efficacy and safety of GS is of importance since its use worldwide is increasing. Therefore, the present study aimed to map and grade the diverse health outcomes associated with GS using an umbrella review approach.
Methods: Medline, Cinahl and Embase databases were searched until 1 April 2020. An
umbrella review of systematic reviews and meta-analyses of randomized controlled trials
(RCTs) was carried out. The evidence from the RCTs was graded using the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) tool.
Results: From 140 articles returned, 11 systematic reviews, for a total of 21 outcomes (37
RCTs; 3949 participants; almost all using 1500 mg/day), were included. No systematic reviews/
meta-analyses of observational studies were included. Regarding the findings of the metaanalyses, 9/17 outcomes were statistically significant, indicating that GS is more effective than placebo. A high certainty of evidence, as assessed by GRADE, supported the use of GS (versus placebo) in improving the Lequesne Index, joint space width change, joint space width change after 3 years of follow up, joint space narrowing and OA progression. No difference in terms of adverse effects was found between GS and placebo. In systematic reviews, GS was associated with a better glucose profile and a better physical function performance than placebo.
Conclusion: GS, when used as a prescription drug (i.e. crystalline glucosamine sulphate)
at 1500 mg daily dosage, can positively affect the cartilage structure, reduce pain, improve
function and glucose metabolism in people with knee OA, without having a greater incidence
of adverse effects than placebo.

Связанные объекты: #A (найти в новостях).

Текст со страницы (автоматическое получение):
Glucosamine sulphate: an umbrella review of health outcomes
Language :
Abstract :
[en] Background and Aims: Glucosamine sulphate (GS) can be used as background therapy in people affected by knee osteoarthritis (OA). Knowledge regarding the efficacy and safety of GS is of importance since its use worldwide is increasing. Therefore, the present study aimed to map and grade the diverse health outcomes associated with GS using an umbrella review approach.
Methods: Medline, Cinahl and Embase databases were searched until 1 April 2020. An
umbrella review of systematic reviews and meta-analyses of randomized controlled trials
(RCTs) was carried out. The evidence from the RCTs was graded using the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) tool.
Results: From 140 articles returned, 11 systematic reviews, for a total of 21 outcomes (37
RCTs; 3949 participants; almost all using 1500 mg/day), were included. No systematic reviews/
meta-analyses of observational studies were included. Regarding the findings of the metaanalyses, 9/17 outcomes were statistically significant, indicating that GS is more effective than placebo. A high certainty of evidence, as assessed by GRADE, supported the use of GS (versus placebo) in improving the Lequesne Index, joint space width change, joint space width change after 3 years of follow up, joint space narrowing and OA progression. No difference in terms of adverse effects was found between GS and placebo. In systematic reviews, GS was associated with a better glucose profile and a better physical function performance than placebo.
Conclusion: GS, when used as a prescription drug (i.e. crystalline glucosamine sulphate)
at 1500 mg daily dosage, can positively affect the cartilage structure, reduce pain, improve
function and glucose metabolism in people with knee OA, without having a greater incidence
of adverse effects than placebo.
Funders :
on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis
Permalink :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
★★★★  06 марта 2021 года
22:27
Brain stereotactic radiotherapy damages recorded by Functional MRI
★★★  06 марта 2021 года
17:50
Aspects récents des mécanismes neuroendocriniens de la puberté
★★★★  06 марта 2021 года
09:10
Cannabis Consommation Marchandisation Echange d’information
★★  06 марта 2021 года
05:45
A new nucleosomic-based model to identify and diagnose SSc-ILD